EVH earnings

WASHINGTON, May 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2026.Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "I am happy with the strong start to the year. We are on track with our plan and have had successful, on-time oncology launches at both Highmark and Aetna. As we look into 2027 and beyond, we remain focused on both extending our market leadership in oncology and addressing the big opp

WASHINGTON, April 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, before market open, with a conference call to follow at 8 a.m. ET.Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to the call.An audio play

WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025.Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model. We believe our total forecasted revenue growth of approximat

WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to th

Q3 2025 financial results ahead of expectations.Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.Expands leadership team to support accelerating growth.WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We are happy to deliver a strong quarter, in the top half of our guidance for both Ad

Company to Participate in Upcoming Conferences WASHINGTON, Oct. 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates fo

Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

WASHINGTON, May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA. We continue to see a very strong selling environment and we achieved significant organic growth with five

Company to Participate in Upcoming Conferences WASHINGTON, April 10, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolen

Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively.Net loss attributable to common shareholders of Evolent Health, Inc. of $30.6 million for three months ended December 31, 2024 and $93.5 million for the year ended December 31, 2024, resulting in a net loss margin of (4.7)% and (3.7)%, respectively.Adjusted EBITDA of $22.6 million for the three months ended December 31, 2024 and $160.5 million for the year ended December 31, 2024, resulting in an Adjusted EBITDA margin of 3.5% and 6.3%, respectively.Signed contract amendments in all three Performance Suit

Company to Participate in Upcoming Conferences WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its fourth quarter 2024 financial results on Thursday, February 20, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "

Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%.Adjusted EBITDA of $31.8 million resulting in an Adjusted EBITDA margin of 5.1%.Revises outlook for Adjusted EBITDA for 2024.Reiterates average annual long-term revenue and average Adjusted EBITDA growth rate targets.Announces record six new contract agreements in the quarter.WASHINGTON, Nov. 7, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions th

Company to Participate in Upcoming Conferences WASHINGTON, Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9

Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.Adjusted EBITDA of $52.0 million resulting in an Adjusted EBITDA margin of 8.0%.Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance.Reiterates confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024.WASHINGTON, Aug. 8, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care

Company to Participate in Upcoming Conferences WASHINGTON, July 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations

Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.Adjusted EBITDA of $54.1 million resulting in an Adjusted EBITDA margin of 8.5%.Raises revenue outlook for full year 2024 and reiterates full year 2024 Adjusted EBITDA guidance.WASHINGTON, May 9, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended

Company to Participate in Upcoming Conferences WASHINGTON, April 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com. Analysts interested in asking questions during the live call should dial 855.940.

WASHINGTON, Feb. 22, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months and year ended December 31, 2023. Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent stated, "We ended 2023 on a strong note, achieving all of our financial objectives for the year. Annual revenue increased over 45% while we continued to deliver strong earnings, driven by continued underlying growth as well as the successful integration of NIA. I am incredibly proud of our global team who

Company to Participate in Upcoming Investor Conferences   WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its fourth quarter 2023 financial results on Thursday, Feb. 22, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com. Analysts interested in asking questions during the live call should

WASHINGTON, Oct. 10, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2023 financial results on Thursday, Nov. 2, 2023, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, ir.evolenthealth.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and r

WASHINGTON, Aug. 2, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended June 30, 2023. Highlights from the second quarter 2023 announcement include: Revenue of $469.1 million, an increase of $149.2 million, or 46.6%, from the three months ended June 30, 2022.Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million resulting in a net loss margin of (8.8)%.Adjusted EBITDA of $47.4 million resulting in an Adjusted EBITDA margin of 10.1%.Total Lives

WASHINGTON, July 13, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven value-based specialty care solutions to payers and providers, announced today that it will release its second quarter 2023 financial results on Wednesday, August 2, 2023, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers and referencing the "Evolent call" 15 minutes prior to the call. An audio playback of the conference call will be available on Evolent's investor relations website, ir.evolenthealth.c

WASHINGTON, May 3, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended March 31, 2023. Highlights from the first quarter 2023 announcement include: Revenue of $427.7 million, an increase of $130.6 million, or 44.0%, from the three months ended March 31, 2022.Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million resulting in a net loss margin of (6.1)%.Adjusted EBITDA of $50.5 million resulting in an Adjusted EBITDA margin of 11.8%.Total Lives on Platform of 65.6 million, up from 17.9 million for the

Company to Also Host an Investor Day on Tuesday, May 23 WASHINGTON, April 17, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven specialty clinical solutions to payers and providers, today announced it will release its first quarter 2023 financial results on Wednesday, May 3, 2023, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers and referencing the "Evolent Health call" 15 minutes prior to the call. An audio playback of the conference call will be available on Evolent's

WASHINGTON, Feb. 22, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended December 31, 2022. Highlights from the fourth quarter and full year 2022 announcement include: Quarter ended December 31, 2022: Revenue of $382.4 million, an increase of $134.1 million, or 54.0%, from the three months ended December 31, 2021.Net loss attributable to common shareholders of Evolent Health, Inc. of $11.3 million resulting in a net loss margin of (3.0)%.Achieved Adjusted EBITDA of $32.3 million resulting in an Adjusted EBITDA margin of 8.4%.Total

WASHINGTON, Jan. 31, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its fourth quarter 2022 financial results on Wednesday, February 22, 2023 after market close, with a conference call to follow at 5:00 p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers and referencing the "Evolent Health call" 15 minutes prior to the call. An audio playback of the conference call will be available on Evolent's investor relations website,

WASHINGTON, Oct. 13, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its third quarter 2022 operating results on Wednesday, November 2, 2022 after market close, with a conference call to follow at 5:00 p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers and referencing the "Evolent Health call" 15 minutes prior to the call. An audio playback of the conference call will be available on Evolent's investor relations website, ir

WASHINGTON, July 15, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its second quarter 2022 operating results on Tuesday, August 2, 2022 after market close, with a conference call to follow at 5:00 p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers and referencing the "Evolent Health call" 15 minutes prior to the call. An audio playback of the conference call will be available on Evolent's investor relations website, ir.ev

WASHINGTON, April 18, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its first quarter 2022 operating results on Wednesday, May 4, 2022 after market close, with a conference call to follow at 5:00 p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers and referencing the "Evolent Health call" 15 minutes prior to

WASHINGTON, Jan. 25, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its fourth quarter and full year 2021 operating results on Wednesday, February 23, 2022 after market close, with a conference call to follow at 5:00 p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers, and referencing the "Evolent Health call" 15 minutes prior to the call. An audio playback of the conference call will be available on Evolent's investor rela

WASHINGTON, Oct. 18, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its third quarter 2021 operating results on Wednesday, November 3, 2021 after market close, with a conference call to follow at 5:30 p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers, and referencing the "Evolent Health call" 15 minutes prior to the call. An audio playback of the conference call will be available on Evolent's investor relations website, i

WASHINGTON, Aug. 4, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) – Evolent Health, Inc. ("Evolent"), and WindRose Health Investors ("WindRose") announced today that they have entered into a definitive agreement for Evolent to acquire WindRose's portfolio company Vital Decisions for $85 million, with an additional earn out of up to $45 million. Vital Decisions will report into Evolent's specialty management offering, New Century Health, and will be consolidated into Evolent's Clinical Solutions segment. The combination of New Century Health and Vital Decisions brings together two innovative companies that support payers and risk-bearing providers in delivering high-value, lower-cost

WASHINGTON, July 21, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its second quarter 2021 operating results on Wednesday, August 4, 2021 after market close, with a conference call to follow at 6:00 p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers, and referencing the "Evolent Health call" 15 minutes prior to the call. An audio playback of the conference call will be available on Evolent's investor relations website, ir